UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inhibitor clinical burden of disease: a comparative analysis of the CHESS data

Orphanet journal of rare diseases, 2018-11, Vol.13 (1), p.198-198, Article 198

2018

Volltextzugriff (PDF)

Economic Impact of Alvimopan Considering Varying Definitions of Postoperative Ileus

Journal of the American College of Surgeons, 2015-11, Vol.221 (5), p.941-950

2015

Volltextzugriff (PDF)

Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

BMC infectious diseases, 2017-04, Vol.17 (1), p.314-314, Article 314

2017

Volltextzugriff (PDF)

Cost-Utility Analysis of Rimonabant in the Treatment of Obesity

Value in health, 2008-05, Vol.11 (3), p.389-399

2008

Volltextzugriff (PDF)

Turning the Spotlight on Experimental Design in Discrete Choice Experiments—A Focus on Pragmatic Approaches in Health

Value in health, 2013, Vol.16 (1), p.1-2

2013

Volltextzugriff (PDF)

The cost of health care for children and adults with sickle cell disease

American journal of hematology, 2009-06, Vol.84 (6), p.323-327

2009

Volltextzugriff (PDF)

A Predictive Model of Health State Utilities for HIV Patients in the Modern Era of Highly Active Antiretroviral Therapy

Value in health, 2008-12, Vol.11 (7), p.1144-1153

2008

Volltextzugriff (PDF)

Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA

BMC infectious diseases, 2017-01, Vol.17 (1), p.39-39, Article 39

2017

Volltextzugriff (PDF)

Specialty drug coverage varies between health plans' medical and pharmacy benefit policies

Journal of managed care & specialty pharmacy, 2023-06, Vol.29 (6), p.607-613

2023

Volltextzugriff (PDF)

Alvimopan, a Peripherally Acting μ-Opioid Receptor Antagonist, is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial

The Journal of urology, 2014-06, Vol.191 (6), p.1721-1727

2014

Volltextzugriff (PDF)

Trends in the prevalence of thrombocytopenia among individuals iInfected with hepatitis C Virus in the United States, 1999-2008

BMC research notes, 2012-03, Vol.5 (1), p.142-142, Article 142

2012

Volltextzugriff (PDF)

Small Budget Impact Is a Result of Flawed Assumptions and Ignores Questionable Cost-Effectiveness for RSV Prophylaxis

Value in health, 2010-08, Vol.13 (5), p.684-684

2010

Volltextzugriff (PDF)

Factors influencing the participation of gastroenterologists and hepatologists in clinical research

BMC health services research, 2008-10, Vol.8 (1), p.208-208, Article 208

2008

Volltextzugriff (PDF)

Methodological Concerns with Economic Evaluations of Meningococcal Vaccines

PharmacoEconomics, 2010-06, Vol.28 (6), p.449-461

Kauf, Teresa L.

2010

Volltextzugriff (PDF)

Assessment of response shift using two structural equation modeling techniques

Quality of life research, 2013-04, Vol.22 (3), p.461-473

2013

Volltextzugriff (PDF)

The burden of hepatitis C virus infection in children: Estimated direct medical costs over a 10-year period

The Journal of pediatrics, 2006-03, Vol.148 (3), p.353-358

2006

Volltextzugriff (PDF)

Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy

The Journal of dermatological treatment, 2015-11, Vol.26 (6), p.507-513

2015

Volltextzugriff (PDF)

An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection

BMC infectious diseases, 2015-11, Vol.15 (502), p.503-503, Article 503

2015

Volltextzugriff (PDF)

Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV

PharmacoEconomics, 2010-11, Vol.28 (11), p.1025-1039

2010

Volltextzugriff (PDF)

Trends in health care resource use for hepatitis C virus infection in the united states

Hepatology (Baltimore, Md.), 2005-12, Vol.42 (6), p.1406-1413

2005

Volltextzugriff (PDF)

National Trends in the Prevalence of Thrombocytopenia Among Individuals Infected With Hepatitis C Virus, 1999 – 2008

Gastroenterology (New York, N.Y. 1943), 2011, Vol.140 (5), p.S-970-S-970

2011

Volltextzugriff (PDF)

Erratum to: Assessment of response shift using two structural equation modeling techniques

Quality of life research, 2013-04, Vol.22 (3), p.473-473

2013

Volltextzugriff (PDF)

Patientsʼ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection

The patient : patient-centered outcomes research, 2012-12, Vol.5 (4), p.265-278

2012

Volltextzugriff (PDF)

The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry

The American heart journal, 2006, Vol.151 (1), p.206-212

2006

Volltextzugriff (PDF)

Influence of explanatory and confounding variables on HRQoL after controlling for measurement bias and response shift in measurement

Expert review of pharmacoeconomics & outcomes research, 2013-12, Vol.13 (6), p.841-851

2013

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(55)

Sprache

Englisch
(55)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Inhibitor clinical burden of disease: a comparative analysis of the CHESS data

Economic Impact of Alvimopan Considering Varying Definitions of Postoperative Ileus

Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

Cost-Utility Analysis of Rimonabant in the Treatment of Obesity

Turning the Spotlight on Experimental Design in Discrete Choice Experiments—A Focus on Pragmatic Approaches in Health

The cost of health care for children and adults with sickle cell disease

A Predictive Model of Health State Utilities for HIV Patients in the Modern Era of Highly Active Antiretroviral Therapy

Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA

Specialty drug coverage varies between health plans' medical and pharmacy benefit policies

Alvimopan, a Peripherally Acting μ-Opioid Receptor Antagonist, is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial

Trends in the prevalence of thrombocytopenia among individuals iInfected with hepatitis C Virus in the United States, 1999-2008

Small Budget Impact Is a Result of Flawed Assumptions and Ignores Questionable Cost-Effectiveness for RSV Prophylaxis

Factors influencing the participation of gastroenterologists and hepatologists in clinical research

Methodological Concerns with Economic Evaluations of Meningococcal Vaccines

Assessment of response shift using two structural equation modeling techniques

The burden of hepatitis C virus infection in children: Estimated direct medical costs over a 10-year period

Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy

An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection

Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV

Trends in health care resource use for hepatitis C virus infection in the united states

National Trends in the Prevalence of Thrombocytopenia Among Individuals Infected With Hepatitis C Virus, 1999 – 2008

Erratum to: Assessment of response shift using two structural equation modeling techniques

Patientsʼ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection

The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry

Influence of explanatory and confounding variables on HRQoL after controlling for measurement bias and response shift in measurement

Suchergebnisse filtern